Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
Trump pressures 17 pharma CEOs to cut US drug prices
02:28pm, Thursday, 31'st Jul 2025
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
01:48pm, Thursday, 31'st Jul 2025
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont
3 Of The Best SWANs On My Shopping List
10:46am, Thursday, 31'st Jul 2025
Our picks for today are MercadoLibre, Vulcan Materials, and AstraZeneca, with each providing a mix of value and growth. MercadoLibre is Latin America's leading e-commerce and fintech platform with inc
Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana
01:24pm, Wednesday, 30'th Jul 2025
ACCRA, Ghana--(BUSINESS WIRE)-- #AfricaHealth--The strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial
Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure
09:55am, Wednesday, 30'th Jul 2025
AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.
AstraZeneca gets clean bill of health from leading investment bank
09:17am, Wednesday, 30'th Jul 2025
AstraZeneca PLC (LSE:AZN) shares have caught the attention of UBS, which reiterated its 'buy' rating and raised its price target to 14,200p, implying over 27% upside from the current level, after a
AstraZeneca PLC (AZN) Q2 2025 Earnings Call Transcript
06:47pm, Tuesday, 29'th Jul 2025
AstraZeneca PLC (NASDAQ:AZN ) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Andrew P. Barnett - Head of Investor Relations Aradhana Sarin - CFO & Executive Director Da
AstraZeneca CEO: Medical innovation in China is surging
05:37pm, Tuesday, 29'th Jul 2025
"What we have seen in China is really, a substantial return of scientists from the US, but also from the UK and elsewhere, but not because of policy, simply because they could see opportunities in Chi
Why AstraZeneca Stock Was Topping the Market on Tuesday
04:13pm, Tuesday, 29'th Jul 2025
AstraZeneca (AZN 2.99%) reported an estimates-busting quarter Tuesday morning, and a satisfied market rewarded the company for it. At market close the sturdy pharmaceutical stock had risen by nearly 3
AstraZeneca CEO: If you manufacture locally, there's no need to increase prices
12:29pm, Tuesday, 29'th Jul 2025
CNBC's Sara Eisen talks with AstraZeneca Pascal Soriot CEO to discuss the company's most recent quarter, investment in innovation in the U.S., whether tariffs could impact prices, and much more.
AstraZeneca gets £3.3bn lift after upbeat results and steady outlook
10:47am, Tuesday, 29'th Jul 2025
AstraZeneca PLC (LSE:AZN) saw £3.3 billion added to its market value after delivering a strong set of half-year results and confirming its guidance for 2025. The group reported second-quarter revenu
Astrazeneca (AZN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Tuesday, 29'th Jul 2025
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Stree
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
10:16am, Tuesday, 29'th Jul 2025
AZN's second-quarter revenues beat on strong drug sales across Oncology and CVRM despite in-line earnings.
AstraZeneca CEO doubles down on U.S. amid rumors of listing shift
09:57am, Tuesday, 29'th Jul 2025
AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was "rapidly transferring manufacturing" across the Atlantic. "This country [the U.S.] wil
AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook
09:48am, Tuesday, 29'th Jul 2025
AstraZeneca Plc AZN on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by
